Advancing Product Candidates
from Our Own Pipeline

PRINT® Technology

A Simple Elegant Solution for Addressing Challenges in Drug Delivery

Strategic Collaborations

Actively Partnering with
World-class Collaborators

Liquidia Corporation operates through the company’s subsidiaries, Liquidia Technologies, Inc. and RareGen, LLC (RareGen). The Company, through Liquidia Technologies, Inc., is a late-stage clinical biopharmaceutical company focused on the development and commercialization of products using its PRINT technology. It is focused on developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH), and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. RareGen provides commercialization for rare disease pharmaceutical products, such as Sandoz Inc.’s generic treprostinil for PAH.


Improving health with uniform drug particles

Liquidia precisely engineers drug particles in a virtually unlimited number of ways to transform the lives of patients. Watch the video to see how we do it. The precision of our PRINT technology is designed to improve the safety, efficacy and performance of a wide range of therapies, while reducing manufacturing complexity and cost.

© 2021 Liquidia Corporation